Danaher Corporation (DHR) Stock
NYSEDHR has an Alpha Score of 40 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 37 members of Congress disclosed 87 trades in DHR since 2014: 42 purchases and 45 sales, most recently Kevin Hern (partial sale, Sep 2, 2026). 9 of the hedge funds AlphaScala tracks reported DHR in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Lone Pine Capital's at $1.10B. Company insiders reported 0 open-market buys and 6 sales on SEC Form 4 in the 90 days to Nov 20, 2026. Its trailing P/E ratio is 37.4 and its net margin 16.9% (key statistics as of Nov 9, 2026).
What is DHR's Alpha Score?
How it works →Alpha Score of 40 reflects weak overall profile with moderate momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 21, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Danaher Corporation (DHR)?
Most recent: Kevin Hern (partial sale, Sep 2, 2026); records start Feb 25, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-09-02 | partial sale | $1k – $15k |
| Kevin Hern R-OK · House | 2026-08-31 | sale | $15k – $50k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-12-18 | sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-11-13 | partial sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-10-07 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-09-25 | sale | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2025-09-03 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.
Every member of Congress who traded DHR, with filing lags →Which hedge funds own DHR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Lone Pine Capital Steve Mandel | 4.94M | $1.10B | NEW |
| Maverick Capital Lee Ainslie | 2.21M | $490.30M | NEW |
| Marshall Wace | 1.36M | $302.14M | +52575% |
| Tiger Global Chase Coleman | 1.27M | $281.10M | +178% |
| Millennium Management Israel Englander | 1.25M | $276.12M | -42% |
| Viking Global Investors Andreas Halvorsen | 1.04M | $231.20M | NEW |
| Citadel Ken Griffin | 725K | $160.67M | -23% |
| D.E. Shaw David Shaw | 462K | $102.29M | +12% |
| Bridgewater Associates Ray Dalio | 396K | $87.79M | +1443% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Danaher Corporation insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 9, 26 | Milosevich Gregory M | Executive Vice President | SELL | 2.1K | $484K |
| Nov 9, 26 | Mcgrew Matthew | Executive Vice President | SELL | 17.4K | $4.1M |
| Oct 28, 26 | Mcgrew Matthew | Executive Vice President | SELL | 14.2K | $3.3M |
| Oct 28, 26 | Mcgrew Matthew | Executive Vice President | SELL | 15.6K | $3.7M |
| Oct 28, 26 | Bouda Christopher | VP, Chief Accounting Officer | SELL | 4.3K | $1.0M |
| Oct 28, 26 | Bouda Christopher | VP, Chief Accounting Officer | SELL | 3.3K | $763K |
| Aug 21, 26 | Blair Rainer | President & CEO | SELL | 11.3K | $2.5M |
| Aug 21, 26 | Blair Rainer | President & CEO | SELL | 39.2K | $8.6M |
| Aug 21, 26 | Blair Rainer | President & CEO | SELL | 7.8K | $1.7M |
SEC Form 4 filings as of Nov 20, 2026
See cluster-buy signals across all tickers →What are DHR's key statistics?
Key statistics as of Nov 9, 2026
How does DHR's valuation compare with the Healthcare sector?
| Metric | DHR | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 37.4 | 29.1 | 147 |
| Net margin | 16.91% | 3.59% | 223 |
| Return on equity | 8.18% | 3.41% | 255 |
| Dividend yield (payers) | 0.49% | 1.37% | 61 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.
DHR price chart
Powered by TradingViewWhat does Danaher Corporation do?
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services globally, with a primary focus on the United States, China, and other international markets. Operating through three key segments—Biotechnology, Life Sciences, and Diagnostics—the company provides bioprocessing technologies, consumables, and solutions that accelerate therapeutic development and manufacturing, including cell culture media, chromatography resins, filtration systems, and single-use hardware for full manufacturing suites. Its Life Sciences division supports advanced research tools, while Diagnostics offers essential testing and healthcare filtration solutions. Originally founded in 1969 and transformed through strategic acquisitions and divestitures, such as the 2023 spin-off of its environmental solutions into Veralto, Danaher now concentrates on scientific instruments and consumables in the diagnostics and research sector. Employing around 62,000 to 63,000 people under CEO Rainer Blair, Danaher plays a pivotal role in the healthcare and life sciences industries, driving innovation in biopharma production and medical diagnostics with a strong emphasis on recurring revenue streams.